ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY24 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIPGet Free Report) updated its FY24 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $4.26-4.67 for the period, compared to the consensus estimate of $4.48. The company issued revenue guidance of $520-542 million, compared to the consensus revenue estimate of $535.14 million.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ANIP. Truist Financial increased their price objective on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a buy rating in a report on Friday, March 1st. Guggenheim reissued a buy rating and set a $77.00 price objective on shares of ANI Pharmaceuticals in a report on Tuesday, April 23rd. HC Wainwright increased their price objective on ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a buy rating in a report on Monday, March 4th. Finally, Capital One Financial assumed coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They set an overweight rating and a $80.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of Buy and a consensus price target of $80.00.

Check Out Our Latest Stock Report on ANI Pharmaceuticals

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $68.05 on Monday. The firm has a market capitalization of $1.43 billion, a P/E ratio of 42.53 and a beta of 0.80. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. The stock’s 50-day simple moving average is $66.94 and its two-hundred day simple moving average is $59.50. ANI Pharmaceuticals has a twelve month low of $38.91 and a twelve month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIPGet Free Report) last announced its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $131.65 million for the quarter, compared to analyst estimates of $123.02 million. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. As a group, equities analysts anticipate that ANI Pharmaceuticals will post 3.55 EPS for the current fiscal year.

Insider Activity

In other news, CEO Nikhil Lalwani sold 28,965 shares of the stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $65.52, for a total transaction of $1,897,786.80. Following the transaction, the chief executive officer now directly owns 444,981 shares in the company, valued at approximately $29,155,155.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Nikhil Lalwani sold 28,965 shares of the stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $65.52, for a total transaction of $1,897,786.80. Following the transaction, the chief executive officer now directly owns 444,981 shares in the company, valued at approximately $29,155,155.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP James G. Marken sold 24,338 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $66.37, for a total value of $1,615,313.06. Following the transaction, the senior vice president now owns 124,492 shares in the company, valued at $8,262,534.04. The disclosure for this sale can be found here. In the last three months, insiders have sold 176,803 shares of company stock worth $11,695,866. 12.70% of the stock is currently owned by insiders.

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

Recommended Stories

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.